Figures & data
Figure 1 Selection of study population.
![Figure 1 Selection of study population.](/cms/asset/eed80977-a46d-4ee5-ad59-4d934b956410/dhps_a_66835_f0001_b.jpg)
Table 1 Baseline demographics, comorbidity index, and concomitant drug prescriptions
Table 2 Study groups based on current exposure to prescription duloxetine, NSAIDs, or aspirin
Table 3 Doses of duloxetine prescribed across cases and controls
Table 4 UGI events across all cases and each dose of duloxetine in the duloxetine‐only exposure group
Figure 2 Adjusted OR and 95% CI for concomitant exposure to duloxetine, NSAIDs, and aspirin was not associated with an increased risk for UGI bleeding as compared with the risk from exposure to duloxetine only.
![Figure 2 Adjusted OR and 95% CI for concomitant exposure to duloxetine, NSAIDs, and aspirin was not associated with an increased risk for UGI bleeding as compared with the risk from exposure to duloxetine only.](/cms/asset/54450950-6866-4399-ab18-ad1e30bc4873/dhps_a_66835_f0002_b.jpg)
Figure 3 Adjusted OR (95% CI) for the risk of UGI in patients across medication exposure groups.
Abbreviations: OR, odds ratio; CI, confidence interval; UGI, upper gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs.
![Figure 3 Adjusted OR (95% CI) for the risk of UGI in patients across medication exposure groups.](/cms/asset/633da293-78f2-493f-b185-ac3ce5bce8d2/dhps_a_66835_f0003_b.jpg)